Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: A two-year living systematic review update
Therapeutic Advances in Hematology · 2026-11 · 17
DOI: 10.1177/20406207261481200 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 13.11.2026. Verfasst von Luis Carlos Saiz und 4 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: H2020 Marie Skłodowska-Curie Actions, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Background
According to our baseline review, Chimeric Antigen Receptor T-cell (CAR-T) therapies provide longer progression-free survival (PFS), but no overall survival (OS), in recurrent/relapsed B-cell lymphoma (R/R BCL) patients.
Objectives
To provide a timely, rigorous, and continuously updated summary of the evidence available on the role of CAR-T therapy in the treatment of hematologic malignancies.
Design
This is the first update of our living systematic review whose previous baseline report was completed on July 1 st , 2022. Emerging studies on the effect of CAR-T therapy versus other interventions in patients with hematologic malignancies have been monitored and reported.
Methods
Automated living searches were conducted in databases following Epistemonikos procedures. Since the baseline, two reviewers screened titles and abstracts monthly using predefined criteria. This update includes randomized trials published up to 1 May 2025. Additionally, manual searches were also performed every three months. Outcome measures for decision-making included OS, PFS, complete response/remission (CR), relapses and adverse events. We applied the GRADE approach to assess the certainty of the evidence.
Results
Altogether, for the baseline to this update, searches retrieved a total of 2244 articles. After screening, five randomized controlled trials (RCTs) (N = 1670) comparing CAR-T therapy with standard of care (SoC) were included. Compared to SoC for R/R BCL, CAR-T therapy probably increase the PFS [HR 0.47; 95%CI (0.37 to 0.60), moderate certainty; 543 patients]; and may result in longer OS [HR 0.79; 95%CI (0.63 to 0.98); 865 patients, low certainty]. Compared to any other intervention for multiple myeloma (MM), moderate certainty shows that CAR-T therapies may result in increased PFS [HR 0.37; 95%CI (0.19 to 0.69); 805 patients] and CR [RR 3.97; 95%CI (1.20 to 13.17); 805 patients]. For all other outcomes in both diseases evidence is uncertain or very uncertain.
Conclusion
After incorporating the new RCTs into the baseline synthesis, this update indicates that CAR-T therapy may improve PFS, OS and CR outcomes for R/R BCL when compared to SoC, with moderate or low-certainty of evidence depending on the outcome. As for MM, moderate-certainty evidence also leads to better PFS and CR outcomes. Beyond that, the evidence remains uncertain regarding OS and safety outcomes in both diseases. Registration https://doi.org/10.12688/openreseurope.14390.2 , 10.17605/OSF.IO/V6HDX .
Förderung
- H2020 Marie Skłodowska-Curie Actions
- Instituto de Salud Carlos III
Zitieren
APA
Saiz, L. C., Leache, L., Gutiérrez-Valencia, M., Erviti, J., & Reyes, M. X. R. (2026). Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: A two-year living systematic review update. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261481200
Vancouver
Saiz LC, Leache L, Gutiérrez-Valencia M, Erviti J, Reyes MXR. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: A two-year living systematic review update. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261481200
BibTeX
@article{Saiz2026,
author = {Saiz, Luis Carlos and Leache, Leire and Gutiérrez-Valencia, Marta and Erviti, Juan and Reyes, María Ximena Rojas},
title = {Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: A two-year living systematic review update},
journal = {Therapeutic Advances in Hematology},
year = {2026},
volume = {17},
doi = {10.1177/20406207261481200}
}
EUVIMED